HEAL WELL. AGE WELL. LIVE LONGER.(800) 266-7207   ·   contact@clearhealthpass.com
Peptides & healthspan

Small messengers.
Human consequences.

Peptide signaling is one part of the picture. Medical necessity, clinical context and patient safety belong around it.

Peptides as signaling agents

A message is only
part of the story.

The molecule matters. So does the person receiving it.

Explore how a messenger can engage a receptor, then ask the next questions: What response is expected? What evidence supports it? Is the use appropriate for this patient?

Explore the patient-safety story↗

General biology: Signaling Molecules and Their Receptors, NCBI Bookshelf ↗. This illustration is not evidence for any CHP therapy.

PEPTIDE / SIGNAL EXPLORERMESSENGERRECEPTORDrag to rotate

Small messenger. Specific conversation.

Many peptides act as biological messengers. Their effects depend on the molecule, its receptor and the surrounding biology. A signal is not automatically a benefit.

Conceptual illustration · Not a specific molecule or a clinical prediction
Planned, not launched. No peptide service or research enrollment is offered here. Research interests are hypotheses, not established benefits.
Why this belongs in the story

Beyond the molecule.
Build the pathway.

A peptide is only one part of the picture. Who evaluates the patient? Where does the supply come from? How are consent, follow-up and evidence handled?

Clear Health Pass plans three pathways, each with separate roles and permissions. The model is designed around service infrastructure and research support; a research-use-only label is never a patient-release authorization.

Explore the model

Three pathways. Distinct roles.

Select a pathway to explore the business, the gate and the status.

01 / Cash-pay consumer telehealth

Care, connected.

A planned service platform connecting patients with independent licensed clinical practices for assessment, testing and follow-up. Any prescribing decision belongs to the clinician; dispensing belongs to the patient’s chosen licensed pharmacy.

No prescription or outcome is promised.

What must happen

State-by-state clinical, telehealth and pharmacy clearance; substance-specific eligibility.

Status

Not launched. Subject to clearances.

Research interests

Questions worth studying.

Proposed areas of inquiry. These are not announced trials or treatment indications.

Metabolic health

Metabolic and weight-management research; sequenced metabolic regimens described at a functional level.

Study design, authorization, product qualification and evidence generation would each be required. No dose, formulation or use recommendation is provided.

The peptide field guide

One word. Many different worlds.

Peptides are not one product category with one evidence standard. Explore the distinctions.

Established medicines

Metabolic & endocrine therapeutics

Approved brands in the GLP-1 class sit alongside established therapeutic peptides such as insulin analogs, octreotide and teriparatide. Approvals belong to particular products and indications; CHP is not presented as their manufacturer.

Investigational substances

Many peptides discussed in research literature and online markets are not approved medicines and have not been shown safe or effective for any use in people. Specific substances of research interest are identified only in protocol and offering documents, not on this website.

Regulatory status can change, including through the October 30, 2026 HHS draft policy notice. Eligibility must be assessed for the exact substance, route, patient and pathway; no current eligibility determination is made here. Nothing on this page is an offer of, or recommendation to obtain or use, any peptide product.
The research standard

Evidence has to
be built.

TRIBAL would be the research sponsor. CHP would support the work through contracted nonclinical services.

01

Protocol & oversight

Protocol-specific IRB review, participant assessment and informed consent.

02

Qualified supply

Investigational product from qualified U.S. manufacturers, with lot accountability.

03

Documented follow-up

Capture safety and outcomes under the applicable protocol, with data management and biostatistics.

The longer horizon

Shared infrastructure.
Separate permissions.

Early research

Peptide–matrix concepts

Research contemplates the intersection of biologic grafts and peptide approaches. Mechanisms and formulations remain undisclosed. These are not available products.

Context & questions
What is available today?

Rampart™ DL Matrix wound-care tissue is in market. The peptide pathways have not launched. This site offers neither treatment nor enrollment.

Does tribal governance replace FDA requirements?

No. The described program retains separate federal, state, pharmacy, research and institutional requirements. Tribal oversight does not substitute for an IND or another required permission.

Is there a new policy development?

Yes. An October 30, 2026 Federal Register notice announced availability of a draft HHS policy on enforcement discretion for 503A compounding using certain peptide bulk substances. Its effect on company plans is under review.

Are efficacy or healthspan benefits proven?

No peptide-program benefit is established by this website. FDA has identified safety concerns for several substances discussed in this field. Research interests must not be read as proven uses.

Help ask the next question.

For researchers, clinicians and institutional partners.

Discuss the planned program↗